Therapeutic Asset Ratings

8,399 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Talzenna Recurrent Malignant Solid Neoplasm	St. Jude Children's Research Hospital	P1/2	CCC (52)
T-Dxd Non-Small Cell Lung Carcinoma	Iambic Therapeutics, Inc	P1/2	CCC (52)
TESTOSTERONE UNDECYLATE Metabolic Disease	Royal College of Surgeons, Ireland	P1/2	CCC (52)
Therapeutic Autologous Lymphocytes Leukemia	Memorial Sloan Kettering Cancer Center	P1/2	CCC (52)
Tinengotinib Small Cell Lung Carcinoma	TransThera Sciences (Nanjing), Inc.	P1/2	CCC (52)
Tinengotinib Thyroid Cancer	TransThera Sciences (Nanjing), Inc.	P1/2	CCC (52)
Tislelizumab Peritoneal Carcinomatosis	Daping Hospital and the Research Institute of Surgery of the Third Military Medical University	P1/2	CCC (52)
Tislelizumab Relapsed/Refractory Diffuse Large B-Cell Lymphoma	BeiGene	P1/2	CCC (52)
Trastuzumab Deruxtecan Gastroesophageal Junction Adenocarcinoma	National Cancer Institute (NCI)	P1/2	CCC (52)
Trimetazidine Chemotherapy-Induced Neuropathy	Minia University	P1/2	CCC (52)
Uproleselan Therapy Related Acute Myeloid Leukemia And Myelodysplastic Syndrome	National Cancer Institute (NCI)	P1/2	CCC (52)
Veliparib Lung Large Cell Carcinoma	National Cancer Institute (NCI)	P1/2	CCC (52)
Venetoclax Lymphoid Neoplasm	National Cancer Institute (NCI)	P1/2	CCC (52)
(+)-VINCRISTINE Hematopoietic And Lymphoid Cell Neoplasm	Children's Oncology Group	P1/2	CCC (52)
(+)-VINCRISTINE Pediatric Solid Tumor	St. Jude Children's Research Hospital	P1/2	CCC (52)
vx-970 Cancer	Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany	P1/2	CCC (52)
vx-970 Neuroendocrine Carcinoma	National Cancer Institute (NCI)	P1/2	CCC (52)
xnw5004 Neoplasm	Evopoint Biosciences Inc.	P1/2	CCC (52)
YH-003 (HUMANIZED AGONISTIC ANTI-CD40 IGG2 MONOCLONAL ANTIBODY) Cancer	Eucure (Beijing) Biopharma Co., Ltd	P1/2	CCC (52)
Zeprumetostat Childhood Obesity	University of South Carolina	P1/2	CCC (52)
Zimberelimab Colorectal Cancer	Taiho Pharmaceutical Co., Ltd.	P1/2	CCC (52)
Zofin COVID-19	ZEO ScientifiX, Inc.	P1/2	CCC (52)
5-azacytidine Non-Hodgkin Lymphoma	AbbVie	P1/2	CCC (51)
Abemaciclib Colorectal Cancer	National Cancer Institute (NCI)	P1/2	CCC (51)
Adipose-Derived Stromal Vascular Fraction Cells Parkinson Disease	Samuel Vilchez, PhD	P1/2	CCC (51)

Showing 676 to 700 of 8,399 assets

PreviousPage 28 of 336Next